Citations

Clear

3138 citation(s) found for "Smith, AM".

Multiple comorbid neuropathologies in the setting of Alzheimer's disease neuropathology and implications for drug development
Forman, Mark S., DeSanti, Susan, Kozauer, Nicholas, Petersen, Ronald C. , Randolph, Christopher , Isaac, Maria , Mattsson, Niklas , Bain, Lisa J. , Hendrix, James A. , Sims, John R. , Rabinovici, Gil D. , Carrillo, María C. , Miller, David S., Knopman, David S. , Smith, Eric Edward

Mayo Clinic

Alzheimer's & Dementia: Translational Research & Clinical Interventions | September 20, 2016 | Volume: 3 | Issue: 1 | Pages: 83-91

10.1016/j.trci.2016.09.002 | PMID 29067320 Get It

Abstract Dementia is often characterized as being caused by one of several major diseases, such as Alzheimer's disease (AD), cerebrovascular disease, Lewy body disease, or a frontotemporal degeneration. Failure to acknowledge that more than one entity may be present precludes attempts to understand interactive relationships. The clinicopathological studies of dementia demonstrate that multiple pathologic processes often coexist. How overlapping pathologic findings affect the diagnosis and treatment of clinical AD and other dementia phenotypes was the topic taken up by the Alzheimer's Association's Research Roundtable in October 2014. This review will cover the neuropathologic basis of dementia, provide clinical perspectives on multiple pathologies, and discuss therapeutics and biomarkers targeting overlapping pathologies and how these issues impact clinical trials.High prevalence of multiple pathologic findings among individuals with clinical diagnosis of AD suggests that new treatment strategies may be needed to effectively treat AD and other dementing illnesses.
Common fragile sites (CFS) and extremely large CFS genes are targets for human papillomavirus integrations and chromosome rearrangements in oropharyngeal squamous cell carcinoma
Johnson, Sarah H. , Vasmatzis, George , Pauley, Christina E, Tombers, Nicole M. , Kasperbauer, Jan L. , Smith, David I., Gao, Ge , Smith, David I.

Mayo Clinic

Genes, Chromosomes and Cancer | September 16, 2016 | Volume: 56 | Issue: 1 | Pages: 59-74

10.1002/gcc.22415 | PMID 27636103 Get It

Common fragile sites (CFS) are chromosome regions that are prone to form gaps or breaks in response to DNA replication stress. They are often found as hotspots for sister chromatid exchanges, deletions, and amplifications in different cancers. Many of the CFS regions are found to span genes whose genomic sequence is greater than 1 Mb, some of which have been demonstrated to function as important tumor suppressors. CFS regions are also hotspots for human papillomavirus (HPV) integrations in cervical cancer. We used mate‐pair sequencing to examine HPV integration events and chromosomal structural variations in 34 oropharyngeal squamous cell carcinoma (OPSCC). We used endpoint PCR and Sanger sequencing to validate each HPV integration event and found HPV integrations preferentially occurred within CFS regions similar to what is observed in cervical cancer. We also found that many of the chromosomal alterations detected also occurred at or near the cytogenetic location of CFSs. Several large genes were also found to be recurrent targets of rearrangements, independent of HPV integrations, including CSMD1 (2.1Mb), LRP1B (1.9Mb), and LARGE1 (0.7Mb). Sanger sequencing revealed that the nucleotide sequences near to identified junction sites contained repetitive and AT‐rich sequences that were shown to have the potential to form stem‐loop DNA secondary structures that might stall DNA replication fork progression during replication stress. This could then cause increased instability in these regions which could lead to cancer development in human cells. Our findings suggest that CFSs and some specific large genes appear to play important roles in OPSCC. © 2016 Wiley Periodicals, Inc.
Diagnostic Approach to Advanced Fibrotic Interstitial Lung Disease: Bringing Together Clinical, Radiologic, and Histologic Clues
Larsen, Brandon T. , Elicker, Brett M. , Fernández, Jessica , Morvil, Guillermo A. Arbo-Oze de, Pereira, Carlos A.C. , Leslie, Kevin O., Smith, Maxwell L.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | September 15, 2016 | Volume: 141 | Issue: 7 | Pages: 901-915

10.5858/arpa.2016-0299-sa | PMID 27628326 Get It

Context.— Idiopathic pulmonary fibrosis (IPF) is a distinctive clinicopathologic entity and the most common form of progressive diffuse lung scarring in older adults. Idiopathic pulmonary fibrosis manifests histopathologically as the usual interstitial pneumonia pattern. The usual interstitial pneumonia pattern is distinguished by geographically and temporally heterogeneous fibrosis that is peripherally accentuated, often with honeycombing and traction bronchiectasis. Idiopathic pulmonary fibrosis is not the only disease that leads to end-stage lung fibrosis, however, and several other entities may also cause advanced fibrosis. Surgical lung biopsies often present a diagnostic dilemma when they show clear evidence of advanced fibrosis, but the clinical, imaging, and/or histopathologic subcharacteristics suggest something other than IPF. Objective.— To address this dilemma, we review several other fibrotic lung diseases, including connective tissue disease–associated interstitial lung disease, chronic hypersensitivity pneumonitis, advanced pulmonary Langerhans cell histiocytosis, end-stage pulmonary sarcoidosis, Erdheim-Chester disease, Hermansky-Pudlak syndrome, and others, detailing their clinical, radiologic, and histopathologic attributes and emphasizing similarities to and differences from IPF. Data Sources.— Data sources comprised published peer-reviewed literature and personal experience of the authors. Conclusions.— Often, clues in the lung biopsy may offer the first suggestion of a fibrotic lung disease other than IPF, and accurate classification is important for prognosis, treatment, and the development of future therapies.
Use of hydroxyethyl starch in leukocytapheresis procedures does not increase renal toxicity
Harmon, Charles S., Cooling, Laura , Connelly‐Smith, Laura , Mann, Steven A. , Pham, Huy P. , Marques, Marisa B. , Schlueter, Annette J. , Case, Rosemary, King, Karen E., Cataife, Guido, Wu, Yanyun , Wong, Edward C.C. , Winters, Jeffrey L , Pagano, Monica B. , Winters, Jeffrey L. , Pham, Huy P , Schlueter, Annette J , Marques, Marisa B

Mayo Clinic

Transfusion | September 7, 2016 | Volume: 56 | Issue: 11 | Pages: 2848-2856

10.1111/trf.13795 | PMID 27600855 Get It

BACKGROUNDHydroxyethyl starch (HES) is reportedly associated with an increased risk of renal failure and death when used for fluid resuscitation in critically ill patients. HES can be used during therapeutic leukocytapheresis (TL) procedures to enhance cell separation. The purpose of this study was to evaluate the occurrence of adverse events associated with HES during TL procedures.STUDY DESIGN AND METHODSWe performed a retrospective review of patients who underwent TL with and without HES in the period 2009 to 2013 at six academic medical institutions.RESULTSA difference‐in‐difference regression analysis was used to estimate the mean change before and after TL in selected outcomes in the HES group relative to the average change in the non‐HES group. Selected outcomes included serum creatinine, estimated glomerular filtration rate (eGFR), and white blood cell (WBC) count. A total of 195 patients who underwent 278 TL procedures were studied. We found no significant differences in serum creatinine levels and eGFR on Days 1 and 7 after TL procedure between patients who received and those who did not receive HES. The rate of adverse events and overall and early mortality were similar in both groups. Patients with acute myeloid leukemia who received HES had greater WBC reduction when HES was used. Additionally, patients who received HES had improvement in pulmonary leukostasis symptoms.CONCLUSIONHES, used at low doses during TL procedures, was not associated with adverse events previously ascribed to its use as a volume expander.
A Phase I Study of Topotecan, Carboplatin and the PARP Inhibitor Veliparib in Acute Leukemias, Aggressive Myeloproliferative Neoplasms, and Chronic Myelomonocytic Leukemia
Pratz, Keith W. , Gojo, Ivana , Litzow, Mark R. , McDevitt, Michael A. , Ji, Jiuping , Karnitz, Larry M., Herman, James G. , Kinders, Robert J. , Gore, Steven D. , Showel, Margaret M. , Gladstone, Douglas E. , Tsai, Hua-Ling, Rosner, Gary L. , Chen, Alice P. , Karp, Judith E. , Kaufmann, Scott H. , Rudek, Michelle A. , Smith, B. Douglas , Carraway, Hetty E. , Levis, Mark J. , Tsai, Hua‐Ling

Mayo Clinic

Clinical Cancer Research | August 22, 2016 | Volume: 23 | Issue: 4 | Pages: 899-907

10.1158/1078-0432.ccr-16-1274 | PMID 27551000 Get It

Abstract Purpose: The PARP inhibitor veliparib delays DNA repair and potentiates cytotoxicity of multiple classes of chemotherapy drugs, including topoisomerase I inhibitors and platinating agents. This study evaluated veliparib incorporation into leukemia induction therapy using a previously described topotecan/carboplatin backbone. Experimental Design: Employing a 3+3 trial design, we administered escalating doses of veliparib combined with topotecan + carboplatin in relapsed or refractory acute leukemias, aggressive myeloproliferative neoplasms (MPN), and chronic myelomonocytic leukemia (CMML). Results: A total of 99 patients received veliparib 10–100 mg orally twice daily on days 1–8, 1–14, or 1–21 along with continuous infusion topotecan 1.0–1.2 mg/m2/d + carboplatin 120–150 mg/m2/d on days 3–7. The MTD was veliparib 80 mg twice daily for up to 21 days with topotecan 1.2 mg/m2/d + carboplatin 150 mg/m2/d. Mucositis was dose limiting and correlated with high veliparib concentrations. The response rate was 33% overall (33/99: 14 CR, 11 CRi, 8 PR) but was 64% (14/22) for patients with antecedent or associated aggressive MPNs or CMML. Leukemias with baseline DNA repair defects, as evidenced by impaired DNA damage–induced FANCD2 monoubiquitination, had improved survival [HR = 0.56 (95% confidence interval, 0.27–0.92)]. A single 80-mg dose of veliparib, as well as veliparib in combination with topotecan + carboplatin, induced DNA damage as manifested by histone H2AX phosphorylation in CD34+ leukemia cells, with greater phosphorylation in cells from responders. Conclusions: The veliparib/topotecan/carboplatin combination warrants further investigation, particularly in patients with aggressive MPNs, CMML, and MPN- or CMML-related acute leukemias. Clin Cancer Res; 23(4); 899–907. ©2016 AACR.
Intra-Articular Bone Marrow Concentrate Injection Protocol: Short-Term Efficacy in Osteoarthritis
Sampson, Steven , Smith, Jay , Vincent, Hunter, Aufiero, Danielle, Zall, Mona, Botto-van-Bemden, Angie

Mayo Clinic

Regenerative Medicine | August 16, 2016 | Volume: 11 | Issue: 6 | Pages: 511-520

10.2217/rme-2016-0081 | PMID 27527808 Get It

Lingering Problems: A Case Example
Smith, Aynsley M.

Mayo Clinic

Athletic Therapy Today | August 10, 2016 | Volume: 6 | Issue: 5 | Pages: 44-45

10.1123/att.6.5.44 Get It

Characterization of C3 in C3 glomerulopathy
Sethi, Sanjeev , Vrana, Julie A., Theis, Jason D. , Sethi, Amit , Kurtin, Paul J. , Smith, Richard J. , Fervenza, Fernando C. , Zhang, Yuzhou

Mayo Clinic

Nephrology Dialysis Transplantation | August 9, 2016 | Volume: 32 | Issue: 3 | Pages: 459-465

10.1093/ndt/gfw290 | PMID 27507892 Get It

Abstract Background: C3 glomerulopathy (C3G) is caused by overactivity of the alternative pathway of complement that results in bright glomerular C3 staining with minimal or no deposition of immunoglobulins on immunofluorescence microscopy. Laser microdissection and mass spectrometry of the two subtypes, C3 glomerulonephritis (C3GN) and dense deposit disease (DDD), have identified C3 as the predominant glomerular complement protein, although lesser amounts of C9, C5, C6, C7 and C8 are detectable. C3 plays a central role in complement activity, with its proteolytic cleavage first generating C3a and C3b, followed by inactivation of C3b generating iC3b (which includes C3α and C3β), which undergoes further breakdown yielding C3c and terminal breakdown fragment C3dg. The composition of C3 breakdown products in C3G is not known. Methods: In this study, we chose six cases each of C3GN and DDD to analyze the composition of C3 deposits. We analyzed the amino acid sequence of C3 spectra detected by mass spectrometry to determine the relative abundance of C3 fragments in C3G. Thus we were able to determine the amino acid sequences mapping to the various C3 activation products including C3dg, C3α (C3α1 and α2), and C3β that are part of C3b/iC3b/C3c. Results: C3dg is the predominant cleavage product detected with the highest amino acid coverage. The remaining amino acids map to C3α (C3α1 and α2) and C3β. Amino acids mapping to C3a and C3f are absent. Taken together, the C3α and C3β amino acids represent iC3b prior to or after C3c cleavage of C3dg. The C3 spectra for both C3GN and DDD are surprisingly similar. Conclusion: The finding of large amounts of C3dg suggests that C3b deposition in the glomerulus is an active process triggered by thioester binding of C3b to the glycocalyx overlying the glomerular endothelial cells and glomerular basement membrane. Regulatory protein-mediated inactivation of C3b results in the generation of iC3b. After additional cleavages, mostly C3dg remains.
Radiogenomics to characterize regional genetic heterogeneity in glioblastoma
Hu, Leland , Ning, Shuluo , Eschbacher, Jennifer , Baxter, Leslie C. , Gaw, Nathan , Ranjbar, Sara , Plasencia, Jonathan D. , Dueck, Amylou C. , Peng, Sen, Smith, Kris A. , Karis, John P. , Quarles, C. Chad , Loftus, Joseph C. , Jenkins, Robert B. , Sicotte, Hugues , Kollmeyer, Thomas M. , Elmquist, William F. , Frakes, David , Swanson, Kristin R. , Tran, Nhan L. , Mitchell, J. Ross , Eschbacher, Jennifer M., Plasencia, Jonathan, Nakaji, Peter , O'Neill, Brian P, Elmquist, William, Hoxworth, Joseph M. , Sarkaria, Jann, Dueck, A. C. , Baxter, Leslie C. , Wu, Teresa , O’Neill, Brian Patrick , Sarkaria, Jann N. , Swanson, Kristin R , Li, Jing , Kollmeyer, Thomas , Tran, Nhan L

Mayo Clinic

Neuro-Oncology | August 9, 2016 | Volume: 19 | Issue: 1 | Pages: 128-137

10.1093/neuonc/now135 | PMID 27502248 Get It

AbstractBackgroundGlioblastoma (GBM) exhibits profound intratumoral genetic heterogeneity. Each tumor comprises multiple genetically distinct clonal populations with different therapeutic sensitivities. This has implications for targeted therapy and genetically informed paradigms. Contrast-enhanced (CE)-MRI and conventional sampling techniques have failed to resolve this heterogeneity, particularly for nonenhancing tumor populations. This study explores the feasibility of using multiparametric MRI and texture analysis to characterize regional genetic heterogeneity throughout MRI-enhancing and nonenhancing tumor segments.MethodsWe collected multiple image-guided biopsies from primary GBM patients throughout regions of enhancement (ENH) and nonenhancing parenchyma (so called brain-around-tumor, [BAT]). For each biopsy, we analyzed DNA copy number variants for core GBM driver genes reported by The Cancer Genome Atlas. We co-registered biopsy locations with MRI and texture maps to correlate regional genetic status with spatially matched imaging measurements. We also built multivariate predictive decision-tree models for each GBM driver gene and validated accuracies using leave-one-out-cross-validation (LOOCV).ResultsWe collected 48 biopsies (13 tumors) and identified significant imaging correlations (univariate analysis) for 6 driver genes: EGFR, PDGFRA, PTEN, CDKN2A, RB1, and TP53. Predictive model accuracies (on LOOCV) varied by driver gene of interest. Highest accuracies were observed for PDGFRA (77.1%), EGFR (75%), CDKN2A (87.5%), and RB1 (87.5%), while lowest accuracy was observed in TP53 (37.5%). Models for 4 driver genes (EGFR, RB1, CDKN2A, and PTEN) showed higher accuracy in BAT samples (n = 16) compared with those from ENH segments (n = 32).ConclusionMRI and texture analysis can help characterize regional genetic heterogeneity, which offers potential diagnostic value under the paradigm of individualized oncology.